The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable
For information, this appraisal has been rescheduled to allow the company to include important data to be presented in their submission. Therefore, this appraisal will be removed from the NICE’s reporting targets for timelines and the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorisation. The appraisal is now anticipated to begin during late October 2020 when we will write to you about how you can get involved.